MedTrace Logo

Association of Survival With Maintenance Therapy in Patients With Metastatic Breast Cancer After First-line Chemotherapy

NCT04258163 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 760

Last updated 2020-02-10

No results posted yet for this study

Summary

To investigate the benefits and risks of maintenance chemotherapy (MCT), maintenance endocrine therapy (MET) and none maintenance therapy after first-line treatment of metastatic breast cancer (MBC).

Conditions

Interventions

DRUG

Capecitabine

1000-1250 mg/m 2 PO twice daily days 1-14, cycled every 28 days

DRUG

Liposomal doxorubicin

50 mg/m 2 IV day 1, cycled every 28 days

DRUG

Gemcitabine

800-1200 mg/m 2 IV days 1, 8, and 15, cycled every 28 days

DRUG

Fulvestrant

500mg IH Days 0, 14, 28, then every 28 days

DRUG

Anastrozole

1mg PO qd

DRUG

Letrozole

2.5mg PO qd

Sponsors & Collaborators

  • Sun Yat-sen University

    collaborator OTHER

  • First People's Hospital of Foshan

    collaborator OTHER

  • Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

    lead OTHER

Principal Investigators

  • Herui Yao, PhD · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-01-01
Primary Completion
2019-06-01
Completion
2019-07-01
FDA Drug
Yes

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04258163 on ClinicalTrials.gov